LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
UPPSALA, SWEDEN – LIDDS AB (publ) ("LIDDS" or the "Company") announced today the outcome of the subscription of shares in the incentive programs 2017/2020. Last day of subscription was on October 15, 2020.
At the extraordinary general meeting on October 6, 2017 it was resolved to issue warrants and implement two incentive programs 2017/2020 (the ”Incentive Programs 2017/2020”). The incentive program was directed to the members of the board of directors, to CEO and other key persons. All warrants in the Incentive Programs 2017/2020 was subscribed for.
In total, warrants corresponding to 0.8 percent of the total 1,000,000 number of warrants issued was exercised, which correspond to a dilution of 0.027 percent in the Company. Price of warrants were 14.80 SEK (closing price at the same day was 14.85 SEK).
Through the Incentive Programs 2017/2020 the Company’s share capital will increase from SEK 1,572,361.81 to SEK 1,572,791.75 and the number of shares will increase from 29,667,204 shares to 29, 675, 316 shares.
Monica Wallter, CEO
E-mail: email@example.com | Phone: 0737-07 09 22
Anja Peters, CFO
E-mail: firstname.lastname@example.org | Phone: +46 733-26 00 00
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, email@example.com, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.